J. H. Turner

发表

J. Turner, J. H. Turner, J. Turner, 2021, Cancer biotherapy & radiopharmaceuticals.

Pancreatic Neuroendocrine Tumor Control: Durable Objective Response to Combination 177Lu-Octreotate-Capecitabine-Temozolomide Radiopeptide Chemotherapy

J. Turner, P. Claringbold, J. H. Turner, 2015, Neuroendocrinology.

NeuroEndocrine Tumor Therapy with Lutetium-177-octreotate and Everolimus (NETTLE): A Phase I Study.

J. Turner, P. Claringbold, J. H. Turner, 2015, Cancer biotherapy & radiopharmaceuticals.

Phase I-II study of radiopeptide 177Lu-octreotate in combination with capecitabine and temozolomide in advanced low-grade neuroendocrine tumors.

J. Turner, P. Claringbold, Rich Price, 2012, Cancer biotherapy & radiopharmaceuticals.

Phase II study of radiopeptide 177Lu-octreotate and capecitabine therapy of progressive disseminated neuroendocrine tumours

J. Turner, Phillip G. Claringbold, Paul A. Brayshaw, 2011, European Journal of Nuclear Medicine and Molecular Imaging.

CYCLOSPORINE A IMMUNOSUPPRESSION IN SHEEP WITH RESPONSE ENHANCEMENT BY CONCOMITANT KETOCONAZOLE

J. Reynoldson, J. Turner, H. O'Donoghue, 1996, Clinical and experimental pharmacology & physiology.

Localization of 11C-radiopharmaceuticals in the Greene melanoma of hamsters

D. Comar, J. Turner, M. Maziére, 2004, European Journal of Nuclear Medicine.

Orthotopic xenografts of human melanoma and colonic and ovarian carcinoma in sheep to evaluate radioimmunotherapy.

J. Turner, A. Rose, W. Penhale, 1998, British Journal of Cancer.

Review of Gallium-68 PSMA PET/CT Imaging in the Management of Prostate Cancer

N. Lenzo, J. Turner, D. Meyrick, 2018, Diagnostics.

Synovial cyst of spinal facet. Case report.

S. S. Winkler, C. Kao, J. Turner, 1974, Journal of neurosurgery.

Myeloid Toxicity of Radionuclide Cancer Therapy.

M. Kesavan, J. Turner, J. H. Turner, 2021, Cancer biotherapy & radiopharmaceuticals.

Recent advances in theranostics and challenges for the future.

J. Turner, J. H. Turner, J. Turner, 2018, The British journal of radiology.

A model of multiple myeloma: culture of 5T33 murine myeloma cells and evaluation of tumorigenicity in the C57BL/KaLwRij mouse.

J. Turner, H. O'Donoghue, P. Claringbold, 1992, British Journal of Cancer.

Validation of prospective whole-body bone marrow dosimetry by SPECT/CT multimodality imaging in 131I-anti-CD20 rituximab radioimmunotherapy of non-Hodgkin’s lymphoma

J. Bouček, J. Turner, J. H. Turner, 2005, European Journal of Nuclear Medicine and Molecular Imaging.

Responsible Radionuclide Cancer Care.

J. Turner, J. H. Turner, J. Turner, 2021, Cancer biotherapy & radiopharmaceuticals.

Automated module radiolabeling of peptides and antibodies with gallium-68, lutetium-177 and iodine-131.

J. Turner, M. De Decker, J. H. Turner, 2012, Cancer biotherapy & radiopharmaceuticals.

Imaging of Early Response to Predict Prognosis in the First-Line Management of Follicular Non-Hodgkin Lymphoma with Iodine-131-Rituximab Radioimmunotherapy

J. Bouček, A. McQuillan, M. Kesavan, 2017, Diagnostics.

Phase II study of first-line 131I-rituximab radioimmunotherapy in follicular non-Hodgkin lymphoma and prognostic 18F-fluorodeoxyglucose positron emission tomography

A. McQuillan, W. Macdonald, J. Turner, 2015 .

A phase II study of treatment of painful multifocal skeletal metastases with single and repeated dose samarium-153 ethylenediaminetetramethylene phosphonate.

J. Turner, P. Claringbold, J. H. Turner, 1991, European journal of cancer.

A phase I study of samarium-153 ethylenediaminetetramethylene phosphonate therapy for disseminated skeletal metastases.

J. Turner, P. Claringbold, E. Hetherington, 1989, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Radioimmunotherapy of relapsed indolent non-Hodgkin lymphoma with 131I-rituximab in routine clinical practice: 10-year single-institution experience of 142 consecutive patients.

J. Turner, M. Leahy, J. H. Turner, 2011, Blood.

Technetium-99m antimony colloid for bone-marrow imaging.

J. Papadimitriou, J. Turner, A. Martindale, 1980, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

Continuous imaging of regional myocardial blood flow in dogs using krypton-81m.

T. Jones, A. Selwyn, M. Raphael, 1976, Cardiovascular research.

Iodine-131 rituximab radioimmunotherapy with BEAM conditioning and autologous stem cell transplant salvage therapy for relapsed/refractory aggressive non-Hodgkin lymphoma.

J. Turner, J. Cooney, J. H. Turner, 2012, Cancer biotherapy & radiopharmaceuticals.

Treatment of Lymphoma with 131I-Chimeric Monoclonal Antibodies

J. Turner, J. H. Turner, 2012 .

Outpatient therapeutic nuclear oncology

J. Turner, J. H. Turner, J. Harvey Turner, 2012, Annals of Nuclear Medicine.

Australasian Gastrointestinal Trials Group (AGITG) CONTROL NET Study: Phase II study evaluating the activity of 177Lu-Octreotate peptide receptor radionuclide therapy (LuTate PRRT) and capecitabine, temozolomide CAPTEM)—First results for pancreas and updated midgut neuroendocrine tumors (pNETS, mNET

V. Gebski, D. Bailey, N. Pavlakis, 2020 .

Multicenter phase II clinical study of iodine-131-rituximab radioimmunotherapy in relapsed or refractory indolent non-Hodgkin's lymphoma.

R. Hicks, J. Seymour, J. Turner, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

F-fl uorodeoxyglucose positron emission tomography

A. McQuillan, W. Macdonald, J. H. Turner, 2015 .

An introduction to the clinical practice of theranostics in oncology.

J. Turner, J. H. Turner, J Harvey Turner, 2018, The British journal of radiology.

Myocardial hibernation identified by hyperbaric oxygen treatment and echocardiography in postinfarction patients: comparison with exercise thallium scintigraphy.

J. O'Shea, H. Oxer, G. Lane, 1992, American heart journal.

Chemotherapy Combined with Radionuclide Therapy

P. Claringbold, J. H. Turner, J. Turner, 2012 .

Outpatient 131I-Rituximab Radioimmunotherapy for Non-Hodgkin Lymphoma: A Study in Safety

P. Calais, J. H. Turner, 2012, Clinical Nuclear Medicine.

Long‐term efficacy and safety of chemotherapy‐free first‐line iodine‐131‐rituximab radioimmunotherapy of follicular lymphoma

A. McQuillan, M. Kesavan, Ghassan Zammar, 2021, British journal of haematology.

Radiation safety of outpatient 177Lu-octreotate radiopeptide therapy of neuroendocrine tumors

P. Calais, J. H. Turner, J. Turner, 2014, Annals of Nuclear Medicine.

Perspective: multimodality radionuclide therapy of progressive disseminated lymphoma and neuroendocrine tumors as a paradigm for cancer control.

J. Turner, J. H. Turner, J. Turner, 2012, Cancer biotherapy & radiopharmaceuticals.

Management of fear of radiation exposure in carers of outpatients treated with iodine-131

A. Page, P. Calais, J. H. Turner, 2012, Annals of Nuclear Medicine.

Myelotoxicity of Peptide Receptor Radionuclide Therapy of Neuroendocrine Tumors: A Decade of Experience.

M. Kesavan, J. Turner, J. H. Turner, 2016, Cancer biotherapy & radiopharmaceuticals.

Repeat treatment with iodine-131-rituximab is safe and effective in patients with relapsed indolent B-cell non-Hodgkin's lymphoma who had previously responded to iodine-131-rituximab.

R. Hicks, J. Seymour, J. Turner, 2008, Annals of oncology : official journal of the European Society for Medical Oncology.

Rheumatoid C1—C2 dislocation: pathogenesis and treatment reconsidered

S. S. Winkler, B. Messert, C. Kao, 1974 .

Pelvic fractures diagnosed by bone scintigraphy in patients with normal radiographs after a fall

S C Stevens, T A Male, J H Turner, 1999, The Medical journal of Australia.

Hematological Toxicity of Combined 177Lu-Octreotate Radiopeptide Chemotherapy of Gastroenteropancreatic Neuroendocrine Tumors in Long-Term Follow-Up

M. Kesavan, J. Turner, P. Claringbold, 2014, Neuroendocrinology.

Salvage Radiopeptide Therapy of Advanced Castrate-Resistant Prostate Cancer with Lutetium-177-Labeled Prostate-Specific Membrane Antigen: Efficacy and Safety in Routine Practice.

N. Lenzo, G. Cardaci, M. Kesavan, 2018, Cancer biotherapy & radiopharmaceuticals.

Efficacy and Haematologic Toxicity of Palliative Radioligand Therapy of Metastatic Castrate-Resistant Prostate Cancer with Lutetium-177-Labeled Prostate-Specific Membrane Antigen in Heavily Pre-Treated Patients

N. Lenzo, G. Cardaci, M. Kesavan, 2021, Diagnostics.

Labeling of monoclonal antibodies with samarium-153 for combined radioimmunoscintigraphy and radioimmunotherapy.

J. Turner, G. Boniface, J. Morris, 1989, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

Optimization of technetium-99m Sestamibi single-photon emission tomography to define multidrug resistance with confidence

R. Moorin, J. H. Turner, A. Davison, 2004, Nuclear medicine communications.

Philosophy of Cancer Theranostics.

J. Turner, J. H. Turner, 2022, Cancer biotherapy & radiopharmaceuticals.

Pancreatic vasoactive intestinal polypeptide‐oma as a cause of secretory diarrhoea

D. Cullen, J. Turner, J. H. Turner, 2000, Journal of gastroenterology and hepatology.

Cyclosporin immunosuppression of sheep: pharmacokinetics and allograft survival.

K. Ilett, L. Hackett, H. O'Donoghue, 2001, Veterinary immunology and immunopathology.

Long‐term survival and toxicity in patients with neuroendocrine tumors treated with 177Lu‐octreotate peptide radionuclide therapy

W. Macdonald, J. Turner, D. Ransom, 2022, Cancer.

Therapies for the medical management of persistent hypoglycaemia in two cases of inoperable malignant insulinoma.

P. G. Fegan, D. Henley, J. Turner, 2010, European journal of endocrinology.

131I-Anti CD20 radioimmunotherapy of relapsed or refractory non-Hodgkins lymphoma: a phase II clinical trial of a nonmyeloablative dose regimen of chimeric rituximab radiolabeled in a hospital.

J. Bouček, J. Turner, M. Leahy, 2003, Cancer biotherapy & radiopharmaceuticals.

Theranostic Outcomes in Clinical Practice of Oncology: What, So What, Now What? What's More.

J. Turner, J. H. Turner, J. Turner, 2019, Cancer biotherapy & radiopharmaceuticals.

166Ho‐microsphere liver radiotherapy: a preclinical SPECT dosimetry study in the pig

P. Norman, R. Lambrecht, J. Turner, 1994, Nuclear medicine communications.

First results for Australasian Gastrointestinal Trials Group (AGITG) control net study: Phase II study of 177Lu-octreotate peptide receptor radionuclide therapy (LuTate PRRT) +/- capecitabine, temozolomide (CAPTEM) for midgut neuroendocrine tumors (mNETs).

V. Gebski, D. Bailey, N. Pavlakis, 2020 .

Personalized dosimetry of 131I-rituximab radioimmunotherapy of non-hodgkin lymphoma defined by pharmacokinetics in bone marrow and blood.

J. Bouček, J. H. Turner, J. Turner, 2014, Cancer biotherapy & radiopharmaceuticals.

Solace for the Cankered Soul.

J. H. Turner, 2023, Cancer biotherapy & radiopharmaceuticals.

Radiopharmaceutical therapy of 5T33 murine myeloma by sequential treatment with samarium-153 ethylenediaminetetramethylene phosphonate, melphalan, and bone marrow transplantation.

H. O'Donoghue, P. Claringbold, J. Berger, 1993, Journal of the National Cancer Institute.

Cancer Care by Committee to be Superseded by Personal Physician-Patient Partnership Informed by Artificial Intelligence.

J. Turner, J. H. Turner, J. Turner, 2023, Cancer biotherapy & radiopharmaceuticals.

Standard Operating Procedure for Prospective Individualised Dosimetry for [131]I-rituximab Radioimmunotherapy of Non-Hodgkin's Lymphoma

P. Calais, J. H. Turner, 2012, World journal of nuclear medicine.